Bank of New York Mellon Corp Buys 14,352 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Bank of New York Mellon Corp boosted its position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 32.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 58,087 shares of the company’s stock after acquiring an additional 14,352 shares during the period. Bank of New York Mellon Corp owned 0.11% of Tyra Biosciences worth $929,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. RA Capital Management L.P. increased its stake in shares of Tyra Biosciences by 43.9% in the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock worth $170,832,000 after purchasing an additional 3,180,155 shares in the last quarter. BVF Inc. IL boosted its holdings in Tyra Biosciences by 70.1% in the 1st quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock worth $76,444,000 after buying an additional 1,921,599 shares during the period. Vanguard Group Inc. grew its position in shares of Tyra Biosciences by 18.6% during the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock worth $14,757,000 after purchasing an additional 140,833 shares in the last quarter. Kynam Capital Management LP grew its position in shares of Tyra Biosciences by 51.4% during the first quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock worth $8,449,000 after purchasing an additional 175,000 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Tyra Biosciences by 8.8% during the 4th quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock valued at $1,419,000 after purchasing an additional 8,324 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Todd Harris sold 5,698 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $24.31, for a total value of $138,518.38. Following the completion of the sale, the chief executive officer now directly owns 1,496,729 shares of the company’s stock, valued at approximately $36,385,481.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 15.40% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on TYRA shares. Wedbush reissued an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a report on Thursday, August 8th. Piper Sandler assumed coverage on shares of Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $23.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, July 3rd. Finally, Oppenheimer lifted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Tyra Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $26.40.

Tyra Biosciences Stock Performance

Shares of TYRA opened at $24.36 on Friday. The stock has a market capitalization of $1.28 billion, a PE ratio of -14.50 and a beta of 1.01. The company’s fifty day moving average is $21.29 and its 200 day moving average is $18.72. Tyra Biosciences, Inc. has a fifty-two week low of $10.38 and a fifty-two week high of $25.14.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. As a group, research analysts forecast that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.